1. Home
  2. Directory
  3. New York
  4. Worcester
  5. Family Medicine
  6. NPI Profile
  7. Prescriptions 1326106956

THOMAS JOHN KUETTEL M.D.
Prescription History 1326106956
Family Medicine - Addiction Medicine in Worcester, NY

NPI Status: Active since December 05, 2006

Contact Information

9556 STATE HIGHWAY 7, UNIT 2
WORCESTER, NY
ZIP 12197
Phone: (518) 281-7987
Fax: (607) 397-4052

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for THOMAS JOHN KUETTEL M.D., an active Addiction Medicine specialist practicing in Worcester, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 81 documented patient claims. Among these therapy options, the most frequently utilized medication is Buprenorphine-Naloxone, which accounts for 39 claims alone.

Medication Index

B
S
Z
No matching medications currently found on file.

Buprenorphine-Naloxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 1,080
NY State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills49.6
Peer Average Days Supply1,192
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,357.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$137.38

State Avg Cost Per Claim

$212.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Suboxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 775
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply641
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,643.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$601.39

State Avg Cost Per Claim

$543.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Zubsolv

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Family Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.6
Peer Average Days Supply442
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,972.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$906.61

State Avg Cost Per Claim

$541.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like THOMAS JOHN KUETTEL M.D. provides transparency into local medical care patterns within Worcester, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Addiction Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.